[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Kikuchi M, Kamei S, Morirama Y, Tuchiya T, Miwa K, Yokoi S, Nakano M, Ehara H, Deguchi T, Hirose Y: [Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin)]. Hinyokika Kiyo; 2008 Aug;54(8):557-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin)].
  • A 52-year-old woman was referred to our hospital for treatment of urachal cancer.
  • Computed tomography and magnetic resonance imaging showed a non-papillary sessile tumor, which was located on the dome of the bladder and invaded the small intestine.
  • The tumor was diagnosed as Sheldon's stage IIIC urachal cancer.
  • After three courses of neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin), the tumor was reduced from 7 x 6 cm to 5.5 x 5 cm in size.
  • Consequently, the patient underwent an en-bloc resection of the urachal tumor with the dome of the bladder and the parts of the ileum invaded by the tumor.
  • One course of adjuvant chemotherapy (FOLFOX4) was performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Ileal Neoplasms / drug therapy. Neoadjuvant Therapy. Urachus. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Middle Aged. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Urachal cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788447.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


2. Hongoh S, Nomoto T, Kawakami M, Hanai K, Inatsuchi H, Terachi T: [Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report]. Hinyokika Kiyo; 2010 Feb;56(2):107-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report].
  • Cystoscopy revealed a papillary tumor at the urinary bladder dome.
  • Abdominal magnetic resonance imaging (MRI) and computed tomography(CT) demonstrated a tumor extending from the umbilicus to the bladder dome.
  • Transurethral resection of bladder tumor (TUR-Bt) was performed and histopathological findings revealed adenocarcinoma.
  • The tumor was diagnosed as stage IIIA urachal carcinoma, and en bloc segmental resection was performed.
  • After two courses of combination chemotherapy with methotrexate (MTX), 5-fluorouracil (5-FU), epirubicin (epiADM), and cisplatin (CDDP), the multiple lung metastases completely disappeared.
  • The patient has survived 23 months to date with no evidence of disease and is receiving adjuvant chemotherapy with tegafur uracil.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185997.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Watanabe Y, Itoh S, Mitsuhata N: [Urachal carcinoma treated with neoadjuvant intra-arterial chemotherapy: a case report]. Hinyokika Kiyo; 2004 Oct;50(10):713-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urachal carcinoma treated with neoadjuvant intra-arterial chemotherapy: a case report].
  • Ultrasonography and computed tomography demonstrated a tumor at the bladder dome.
  • Neoadjuvant intra-arterial chemotherapy with cisplatin, adriamycin and angiotensin II was performed and 40% reduction of tumor size was noted 3 weeks after this therapy.
  • Augmentation ilealcystoplasty was subsequently performed to secure bladder capacity.
  • Adjuvant chemotherapy (UFT) was given for 1 year.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Agents / administration & dosage. Tegafur / administration & dosage. Urachus. Uracil / administration & dosage
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Humans. Infusions, Intra-Arterial. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15575224.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


Advertisement
4. Sekita N, Fujimura M, Arai H, Shibata N, Nishikawa R, Sugano I, Mikami K: [A case of urachal carcinoma treated with S-1/CDDP combination chemotherapy]. Hinyokika Kiyo; 2010 Aug;56(8):447-51
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of urachal carcinoma treated with S-1/CDDP combination chemotherapy].
  • No established treatment exists for urachal carcinoma,except curative resection,and its prognosis is poor.
  • We report a case of advanced urachal carcinoma treated with S-1 and cisplatin combination (S-1/CDDP) chemotherapy.
  • A tumor was detected on the bladder dome and transurethral resection was performed.
  • Magnetic resonance images indicated an extension of this tumor to the retroperioneal space.
  • The tumor was diagnosed as stage IVB (Sheldon's category) urachal carcinoma.
  • After one cycle of S-1/CDDP chemotherapy,the size of the tumor on the bladder dome decreased,after which total cystectomy was performed.
  • The surgical margin of the cystectomy specimen was negative for malignant cells,although poorly differentiated adenocarcinoma was still observed in this specimen.
  • The findings of this study indicate that this therapy might be beneficial for treating advanced urachal carcinomas.
  • This is the second report of successful treatment of advanced urachal carcinoma with S-1/CDDP chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urachus / abnormalities. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Drug Combinations. Female. Humans. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20808064.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Shimasaki N, Yamasaki I, Kamada M, Syuin T: [Two cases of successful treatments with steroid for local and systemic hypersensitivity reaction following intravesical instillation of Bacillus Calmette-Guerin]. Hinyokika Kiyo; 2001 Apr;47(4):281-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of successful treatments with steroid for local and systemic hypersensitivity reaction following intravesical instillation of Bacillus Calmette-Guerin].
  • We have found steroid pulse therapy to be effective and safe for local and systemic adverse reactions of BCG therapy.
  • Case 1: A 57-year-old woman with initial recurrence of urinary bladder carcinoma was treated with transurethral resection.
  • To prevent a second recurrence, she was administered Bacillus Calmette-Guerin (BCG) instillation therapy: 80 mg of BCG, (Tokyo strain) suspended in 40 ml of normal saline, instilled into her bladder weekly.
  • Although she was administered antituberculus, antibiotics and antiallergic drugs, all sign and symptoms were aggravated.
  • She was later diagnosed as having hypersensitive reactions against BCG and treated with steroid pulse therapy.
  • Case 2: A 76-year-old man with initial recurrence of urinary bladder carcinoma was treated with transurethral resection.
  • To prevent a second recurrence, he was instilled the BCG six (6) times.
  • Although no adverse reaction was observed, urinary cytology remained positive (class V) and small papillary tumor was detected at the dome of the bladder.
  • The histopathological findings showed TCC, G3, CIS on the dome of bladder.
  • Then he was again administered the same BCG instillation therapy.
  • Although he was administered antibiotics and antiinflammatory drugs, all signs and symptoms were aggravated.
  • He was diagnosed as having hypersensitive reactions against BCG and was treated with two times of steroid pulse therapy.
  • The signs and symptoms mentioned above were decreased immediately and disappeared after the second steroid pulse therapy.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. BCG Vaccine / adverse effects. Carcinoma, Transitional Cell / therapy. Hypersensitivity / drug therapy. Methylprednisolone / administration & dosage. Prednisolone / administration & dosage. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Female. Humans. Male. Middle Aged. Pulse Therapy, Drug

  • MedlinePlus Health Information. consumer health - Allergy.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11411106.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine; 9PHQ9Y1OLM / Prednisolone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


6. Bryant CS, Shah JP, Triest JA, Schimp VL, Morris RT: Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus. Gynecol Oncol; 2008 Dec;111(3):552-4
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus.
  • BACKGROUND: Chemotherapy remains an essential part of the treatment of advanced ovarian cancer.
  • Intraperitoneal (IP) administration has been demonstrated to provide a survival advantage over intravenous chemotherapy in three phase 3 studies.
  • However, IP catheter complications have been a significant factor in aborting IP therapy.
  • CASE: A 42-year-old woman receiving IP chemotherapy for carcinoma of the ovary presented with complaints of incontinence.
  • Laparoscopic and cystoscopic evaluation demonstrated that the catheter tip had eroded through the dome of the bladder.
  • The catheter was re-secured to the abdominal wall, and the bladder was laparoscopically repaired.
  • IP chemotherapy was resumed 16 days postoperatively without incident.
  • CONCLUSION: This is the first report of an IP catheter eroding through the bladder.
  • Increased usage of IP chemotherapy may offer new challenges in the diagnosis and management of catheter-related complications.
  • [MeSH-major] Catheters, Indwelling / adverse effects. Urinary Bladder Diseases / pathology. Urinary Catheterization / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Infusions, Parenteral. Ovarian Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289650.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Nese N, Kesici G, Lekili M, Isisag A: Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report. Anal Quant Cytol Histol; 2010 Jun;32(3):174-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After the diagnosis of high grade, muscle invasive UCa with intact mucosa on frozen examination of the dome of bladder wall during the radical prostatectomy operation (RPO), partial cystectomy was performed.
  • Six months after the diagnosis, an undifferentiated tumor was detected in a bladder transurethral resection specimen; thus, chemotherapy was given.
  • After 1 course of chemotherapy, the patient was doing well.
  • Although the stage was advanced, the tumor was detected before urachal remnants were destroyed.
  • The treatment choice for urachal carcinomas is cystectomy.
  • Adjuvant chemotherapy and radiotherapy are controversial.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701072.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Entz-Werle N, Marcellin L, Becmeur F, Eyer D, Babin-Boilletot A, Lutz P: The urinary bladder: An extremely rare location of pediatric neuroblastoma. J Pediatr Surg; 2003 Aug;38(8):E10-2
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The urinary bladder: An extremely rare location of pediatric neuroblastoma.
  • Pediatric malignant tumors in the urinary bladder are rare with a high prevalence of rhabdomyosarcomas.
  • A 15-month-old patient was referred to the authors' center because of a urinary bladder tumor.
  • Imaging studies disclosed a solid pelvic mass in the dome of the bladder confirmed by a cystoscopy.
  • Surprisingly, the biopsy done during this procedure confirmed a neuroblastoma with a favorable Shimada classification.
  • This tumor had no bad prognostic factors.
  • But, vessel compression and local infiltration led to delayed surgery, and neoadjuvant chemotherapy was initiated.
  • After chemotherapy, a complete surgical resection was accomplished.
  • Thus, urinary neuroblastoma seems to be a very rare pediatric tumor, but it should be considered in the differential diagnoses of urinary bladder tumor.
  • [MeSH-major] Neuroblastoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12891516.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL: Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol; 2003 Apr;169(4):1295-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience.
  • PURPOSE: Enteric type adenocarcinomas arising in the dome of the bladder or along the urachal ligament are uncommon.
  • To improve our understanding of urachal carcinoma and define outcome with current management, we performed a retrospective review of cases seen at the M. D.
  • Specifically, we sought to evaluate the importance of extent of disease, surgical characteristics and systemic therapy on clinical outcome.
  • RESULTS: Of the 42 patients 7 had clinically evident metastases at diagnosis and 35 had resectable disease that was managed initially with surgery.
  • Overall survival from diagnosis for all 42 patients was 46 months with 40% surviving at 5 years.
  • Median survival from recognition of metastatic disease was 24 months in 26 patients in whom metastases ultimately developed.
  • Chemotherapy for metastatic disease produced only 4 significant responses, including 3 of 9 patients treated with 5-fluorouracil and cisplatin containing regimens.
  • Chemotherapy appropriate for enteric type adenocarcinoma can induce objective responses but meaningful improvement in survival is not yet demonstrated.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urachus. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cancer Care Facilities. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cystectomy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Texas

  • Genetic Alliance. consumer health - Urachal cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12629346.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA91846
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Chen ZF, Wang F, Qin ZK, Dai YP, Zhou FJ, Han H, Liu ZW, Yu SL, Li YH, Ye YL: [Clinical analysis of 14 cases of urachal carcinoma]. Ai Zheng; 2008 Sep;27(9):966-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was to summarize our clinical experience in the diagnosis and treatment of urachal carcinoma.
  • RESULTS: The most common complaints of the 14 patients were hematuria and irrigative bladder symptoms.
  • Cystoscopy mainly revealed broad-based tumors located at the dome of the bladder.
  • Soft-tissue masses between the bladder dome and the abdominal wall were detected by imaging examinations; the wall of the bladder was often invaded.
  • Thirteen patients were found adenocarcinoma, the other one was malignant stromal cell tumor.
  • Seven patients underwent extensive partial excision of the bladder, among which one case developed local recurrence 24 months after operation, while the other six cases were followed up for 14-120 months, with a median follow-up of 42 months without recurrence.
  • Three patients underwent radical bladder resection and urinary diversion, two of which were followed up for 16 months and 84 months respectively without recurrence, while the other one died from surgical complications 3 months after operation.
  • One case underwent partial cystectomy at another hospital developed recurrence 10 months after operation.
  • Three advanced cancer patients received chemotherapy, two of which achieved progression free survival for seven and eight months respectively, while the other one died three months after chemotherapy.
  • CONCLUSIONS: Extensive partial excision of the bladder is recommended for urachal carcinoma.
  • Radical removal of the tumor during the first treatment and comprehensive therapies for advanced cancer patients and patients with recurrence or metastasis after operation are critical to improve the treatment efficacy of urachal carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Cystectomy / methods. Urachus / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799037.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, Schurch B: A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol; 2009 Jun;27(3):397-403
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Although botulinum neurotoxin type A (BoNT/A) intradetrusor injections are a recommended therapy for neurogenic detrusor overactivity (NDO), refractory to antimuscarinic drugs, a standardisation of injection technique is missing.
  • Therefore, we investigated the distribution of the toxin solution after injection into the bladder wall, using magnet resonance imaging (MRI).
  • The volume of the detrusor and the total volume of contrast medium inside and outside the bladder wall were calculated.
  • RESULTS: In all patients, a small volume (mean 17.6%) was found at the lateral aspects of the bladder dome in the extraperitoneal fat tissue, whereas 82.4% of the injected volume reached the target area (detrusor).
  • [MeSH-major] Botulinum Toxins, Type A / administration & dosage. Magnetic Resonance Imaging. Neurotoxins / administration & dosage. Urinary Bladder / pathology. Urinary Bladder, Neurogenic / drug therapy. Urinary Bladder, Neurogenic / pathology
  • [MeSH-minor] Administration, Intravesical. Adolescent. Adult. Aged. Aged, 80 and over. Humans. Injections, Intramuscular. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spinal Cord. 2004 Jun;42(6):338-41 [15007374.001]
  • [Cites] Urology. 2006 Feb;67(2):232-6 [16442605.001]
  • [Cites] JAMA. 2008 May 21;299(19):2261-3 [18492959.001]
  • [Cites] Int Braz J Urol. 2007 Mar-Apr;33(2):132-41 [17488531.001]
  • [Cites] Facial Plast Surg Clin North Am. 2003 Nov;11(4):431-8 [15062246.001]
  • [Cites] Neurochem Int. 2004 Dec;45(7):987-93 [15337297.001]
  • [Cites] Int J Clin Pract Suppl. 2006 Dec;(151):27-32 [17169008.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Mar;292(3):F1065-72 [17107944.001]
  • [Cites] J Urol. 2005 Jul;174(1):196-200 [15947626.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Oct;293(4):F1018-25 [17581924.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):692-7 [10953127.001]
  • [Cites] BJU Int. 2007 Feb;99(2):247-62 [17313422.001]
  • [Cites] J Ultrasound Med. 2003 Aug;22(8):777-82 [12901404.001]
  • [Cites] Rev Urol. 2006 Fall;8(4):198-208 [17192799.001]
  • [Cites] Eur Urol. 2004 Apr;45(4):510-5 [15041117.001]
  • [Cites] Urology. 2004 May;63(5):868-72 [15134967.001]
  • [Cites] Urology. 2008 Mar;71(3):455-9 [18342186.001]
  • [Cites] BJU Int. 2005 Feb;95(3):454 [15679820.001]
  • [Cites] Nat Clin Pract Urol. 2008 Jun;5(6):319-28 [18461049.001]
  • [Cites] Neurourol Urodyn. 2006;25(4):308-17; discussion 318 [16652381.001]
  • [Cites] BJU Int. 2006 Jul;98(1):28-32 [16831138.001]
  • [Cites] Neurochem Int. 2008 May;52(6):1068-75 [18187233.001]
  • [Cites] Eur Urol. 2008 Feb;53(2):275-87 [17988791.001]
  • [Cites] Pediatr Nephrol. 2001 Dec;16(12 ):1122-5 [11793112.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):1058-64 [16517054.001]
  • [Cites] BJU Int. 2006 Apr;97(4):675-8 [16536751.001]
  • [Cites] Urologe A. 2007 Sep;46(9):1211-8 [17684720.001]
  • [Cites] BJU Int. 2006 Jul;98(1):77-82 [16831148.001]
  • (PMID = 19145439.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neurotoxins; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


12. Siefker-Radtke A: Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther; 2006 Dec;6(12):1715-21
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The urachal ligament is an embryologic remnant connecting the dome of the bladder to the umbilicus via the ligamentum commune.
  • Patients usually present with hematuria and upon imaging, have evidence of a cystic or solid structure in the bladder dome or in the bladder midline.
  • Although there are no prospective clinical trials reported to date, large single-institution reports suggest surgical resection with a partial cystectomy and en bloc resection of the urachal ligament with umbilicus as the treatment of choice in the setting of localized disease.
  • Although there is currently no definitive role for neoadjuvant or adjuvant chemotherapy in this tumor, risk factors predicting progression may allow for the selection of patients at higher relapse risk for prospective studies.
  • There is no standard chemotherapy regimen for these patients; however, there is new-found hope with a currently accruing clinical trial exploring a 5-fluorouracil-based chemotherapy combination in this patient population.
  • [MeSH-major] Adenocarcinoma / therapy. Cystectomy / methods. Urachus / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cisplatin / administration & dosage. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Hematuria / etiology. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Factors. Umbilicus / surgery. Urachal Cyst / pathology. Urachal Cyst / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181485.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 29
  •  go-up   go-down


13. Kato K, Arai K, Tanaka Y, Ijiri R, Kato Y, Kigasawa H, Toyoda Y, Aida N, Ohama Y: Epithelioid leiomyosarcoma in a non-immunocompromised infant: additional differential diagnosis of pediatric "round cell tumors". Mod Pathol; 2000 Oct;13(10):1156-60
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid leiomyosarcoma in a non-immunocompromised infant: additional differential diagnosis of pediatric "round cell tumors".
  • Histologically, the tumor was comprised of solid growths of round or polygonal cells with vesicular nuclei and often vacuolated cytoplasm rich in glycogen.
  • The tumor cells were positive for vimentin, NSE, and MIC2, and were negative for desmin and neurofilament.
  • The age, clinical presentation, and histologic findings mostly favored Ewing's sarcoma/primitive neuroectodermal tumor.
  • Silver stain, however, demonstrated well-developed reticulin fibers often outlining individual tumor cells.
  • An expanded panel of immunostains showed that the tumor cells were intensely positive for smooth muscle actin, and ultrastructural study revealed abundant fine cytoplasmic filaments with focal subsarcolemmal densities, various amounts of glycogen, and irregularly arranged, thick basal lamina.
  • The diagnosis of epithelioid leiomyosarcoma was made.
  • Following reduction in tumor size by chemotherapy, the serum NSE level was normalized.
  • From the surgical finding, the primary site was presumed to be the urachus or the urinary bladder dome.
  • [MeSH-major] Abdominal Neoplasms / pathology. Immunocompromised Host. Leiomyosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048812.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


14. Chen KC, Yeh SD, Fang CL, Chiang HS, Chen YK: Lymphoepithelioma-like carcinoma of the urinary bladder. J Formos Med Assoc; 2003 Oct;102(10):722-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the urinary bladder.
  • Lymphoepithelioma-like carcinomas (LELCAs) of the urinary bladder are rare.
  • Bladder sonography revealed a 2 x 3 cm well-defined tumor beneath the bladder mucosa.
  • Radical cystoprostatectomy revealed lymphoepithelioma-like carcinoma with perivesical soft tissue invasion.
  • Cisplatin-based chemotherapy was given.
  • Computed tomography scan demonstrated no evidence of recurrence 26 months postoperatively.
  • Cystoscopy revealed a solid tumor at the bladder dome.
  • Transurethral resection of bladder tumor (TUR-BT) demonstrated lymphoepithelioma-like carcinoma with lamina propria invasion.
  • Tumor cells were positive for cytokeratin but negative for leukocyte common antigen.
  • The patient received adjuvant chemotherapy due to suspicious extravesical tumor spread and high-grade tumor characteristics.
  • After tumor recurrence was identified, TUR-BT was performed again and the surgical specimen showed superficial high-grade LELCA.
  • Pure LELCA is morphologically different from transitional cell carcinoma and has a more favorable prognosis than high-grade, invasive bladder carcinoma if managed appropriately.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14691598.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


15. Hasegawa Y, Kato Y, Wakita T, Hayashi N, Tsukamoto K: [Carcinoma of the urachus: a case report]. Hinyokika Kiyo; 2005 Mar;51(3):191-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy revealed a broad-stalk, nonpapillary tumor at the urinary bladder dome, and cold-punch biopsy proved it to be a mucus-producing adenocarcinoma.
  • Abdominal managnetic resonance imaging demonstrated a tumor extending from the umbilicus to the bladder dome, and chest computed tomography (CT) demonstrated a small lung tumor with calcification.
  • After treatment with three courses of chemotherapy (paclitaxel and carboplatin), the right lung was partially resected.
  • Both indicators returned to their normal ranges after treatment.
  • Such cases require careful observation using imaging modalities and tumor markers.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urachus
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Drug Administration Schedule. Female. Humans. Hysterectomy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Paclitaxel / administration & dosage

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852675.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Neuhaus J, Oberbach A, Schwalenberg T, Stolzenburg JU: Cultured smooth muscle cells of the human vesical sphincter are more sensitive to histamine than are detrusor smooth muscle cells. Urology; 2006 May;67(5):1086-92
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cultured smooth muscle cells of the human vesical sphincter are more sensitive to histamine than are detrusor smooth muscle cells.
  • METHODS: Smooth muscle cells from the bladder dome and internal sphincter were cultured from 5 male patients undergoing cystectomy for bladder cancer therapy.
  • RESULTS: H1R, H2R, and H3R expression was found in tissue and cultured cells.
  • Some of the variability in the outcome of antihistaminic interstitial cystitis therapies might be caused by the ineffectiveness of the chosen antihistaminic or unintentional weakening of sphincteric function.
  • [MeSH-major] Calcium / metabolism. Histamine / pharmacology. Histamine Agonists / pharmacology. Myocytes, Smooth Muscle / secretion. Urinary Bladder / cytology
  • [MeSH-minor] Carbachol / pharmacology. Cells, Cultured. Cystectomy. Humans. Male. Receptors, Histamine / drug effects. Receptors, Histamine / metabolism. Receptors, Histamine H1 / drug effects. Receptors, Histamine H1 / metabolism. Receptors, Histamine H2 / drug effects. Receptors, Histamine H2 / metabolism. Receptors, Histamine H3 / drug effects. Receptors, Histamine H3 / metabolism. Urinary Bladder Neoplasms

  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635523.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine Agonists; 0 / Receptors, Histamine; 0 / Receptors, Histamine H1; 0 / Receptors, Histamine H2; 0 / Receptors, Histamine H3; 820484N8I3 / Histamine; 8Y164V895Y / Carbachol; SY7Q814VUP / Calcium
  •  go-up   go-down


17. Ruggieri MR Sr, Braverman AS, Pontari MA: Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol; 2005 Nov;174(5):1743-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction.
  • PURPOSE: We provide an overview of the medical literature supporting the combined use of muscarinic and alpha-adrenergic antagonist therapy for the treatment of voiding dysfunction.
  • RESULTS: Although the mechanism of action of alpha-adrenergic antagonist therapy for voiding dysfunction has traditionally been assumed to be relaxation of the periurethral, prostatic and bladder neck smooth muscle, substantial evidence supports action at extraprostatic sites involved in micturition, including the bladder dome smooth muscle, peripheral ganglia, spinal cord and brain.
  • Likewise the mechanism of action of anticholinergic therapy has been traditionally assumed to be inhibition of the M3 muscarinic receptor subtypes that mediate normal bladder contractions.
  • However, M2 receptor mediates hypertrophied bladder contractions and there is evidence for an M2 component to the suprasacral control of voiding.
  • Patients who would likely benefit from this combination therapy are men with lower urinary tract symptoms, women with urgency/frequency syndrome (overactive bladder), patients with uninhibited bladder contractions due to neurogenic bladder, and patients with pelvic pain and voiding symptoms, ie interstitial cystitis and chronic prostatitis/chronic pelvic pain syndrome.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Muscarinic Antagonists / therapeutic use. Urination Disorders / drug therapy. Urination Disorders / etiology
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / diagnosis. Quality of Life. Recovery of Function. Risk Assessment. Severity of Illness Index. Treatment Outcome. Urinalysis. Urinary Incontinence / diagnosis. Urinary Incontinence / drug therapy. Urinary Tract Infections / complications. Urinary Tract Infections / diagnosis. Urodynamics

  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1998 Jun;50(2):279-90 [9647869.001]
  • [Cites] Urol Res. 1998;26(2):149-54 [9631949.001]
  • [Cites] J Urol. 1998 Sep;160(3 Pt 1):937-43 [9720591.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 2):R1654-60 [9791087.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Jan 8;63(2):254-61 [9878769.001]
  • [Cites] Life Sci. 1999;64(6-7):429-36 [10069506.001]
  • [Cites] Eur J Pharmacol. 1999 Apr 16;370(3):337-43 [10334511.001]
  • [Cites] Eur Urol. 1999;36(1):1-13 [10364649.001]
  • [Cites] Lancet. 1999 Jun 5;353(9168):1959-64 [10371588.001]
  • [Cites] Biochem J. 1999 Oct 1;343 Pt 1:231-9 [10493934.001]
  • [Cites] Am J Physiol. 1998 Oct;275(4 Pt 2):R1366-73 [9756570.001]
  • [Cites] Circulation. 1999 Dec 7;100(23):2336-43 [10587338.001]
  • [Cites] Exp Cell Res. 2000 Jun 15;257(2):310-9 [10837145.001]
  • [Cites] Urology. 2000 Dec 20;56(6):940-5 [11113737.001]
  • [Cites] Eur J Pharmacol. 2001 Feb 23;414(1):31-5 [11230992.001]
  • [Cites] Expert Opin Pharmacother. 2001 Oct;2(10):1685-701 [11825311.001]
  • [Cites] J Urol. 2002 Mar;167(3):1513-21 [11832780.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):9570-9 [11781325.001]
  • [Cites] J Auton Pharmacol. 2001 Oct-Dec;21(5-6):243-8 [12123469.001]
  • [Cites] J Urol. 2002 Aug;168(2):593-8 [12131316.001]
  • [Cites] Curr Urol Rep. 2002 Aug;3(4):313-8 [12149163.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1621-5 [12352468.001]
  • [Cites] J Urol. 2003 Jun;169(6):2253-6 [12771763.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 May;286(5):R874-80 [14751843.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53 [14769832.001]
  • [Cites] Drugs. 2004;64(15):1643-56 [15257626.001]
  • [Cites] BJU Int. 2004 Oct;94(6):817-20 [15476515.001]
  • [Cites] Br J Urol. 1975 Apr;47(2):193-202 [1148621.001]
  • [Cites] Urology. 1982 Nov;20(5):524-7 [7147531.001]
  • [Cites] J Urol. 1988 Feb;139(2):423-7 [3339764.001]
  • [Cites] Br J Urol. 1989 Jan;63(1):32-5 [2537674.001]
  • [Cites] Br J Pharmacol. 1990 Jan;99(1):197-201 [1970493.001]
  • [Cites] Cell Tissue Res. 1990 Oct;262(1):67-79 [2257617.001]
  • [Cites] J Urol. 1991 Jul;146(1):113-7 [2056568.001]
  • [Cites] Eur Heart J. 1991 Dec;12 Suppl F:83-7 [1666557.001]
  • [Cites] Urology. 1993 Jul;42(1):36-40; discussion 40-1 [7687078.001]
  • [Cites] J Urol. 1994 Apr;151(4):951-4 [7907374.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 1):674-9; discussion 679-80 [7532231.001]
  • [Cites] J Urol. 1995 Apr;153(4):1308-12 [7869533.001]
  • [Cites] J Pharmacol Exp Ther. 1995 May;273(2):959-66 [7752101.001]
  • [Cites] Br J Pharmacol. 1995 Apr;114(8):1710-6 [7599939.001]
  • [Cites] J Urol. 1995 Aug;154(2 Pt 1):396-8 [7541853.001]
  • [Cites] Pharmacol Rev. 1995 Jun;47(2):267-70 [7568329.001]
  • [Cites] Br J Pharmacol. 1995 Jul;115(5):781-6 [8548177.001]
  • [Cites] Urology. 1996 Jun;47(6):840-4 [8677574.001]
  • [Cites] Br J Pharmacol. 1996 Sep;119(1):149-57 [8872368.001]
  • [Cites] Drugs. 1996 Dec;52(6):883-98 [8957159.001]
  • [Cites] J Urol. 1997 Feb;157(2):525-30 [8996348.001]
  • [Cites] Br J Pharmacol. 1997 Jul;121(6):1127-35 [9249248.001]
  • [Cites] Br J Pharmacol. 1997 Nov;122(5):849-58 [9384500.001]
  • [Cites] Neurourol Urodyn. 1998;17(1):31-6 [9453690.001]
  • [Cites] FEBS Lett. 1998 Jan 30;422(2):279-83 [9490024.001]
  • [Cites] Neurourol Urodyn. 1998;17(3):213-29 [9590473.001]
  • [Cites] Urology. 1998 Jun;51(6):861-72 [9609620.001]
  • [Cites] Am J Physiol. 1998 Aug;275(2 Pt 2):F226-9 [9691011.001]
  • (PMID = 16217275.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK043333; United States / NIDDK NIH HHS / DK / R01 DK043333-11
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Muscarinic Antagonists
  • [Number-of-references] 64
  • [Other-IDs] NLM/ NIHMS353504; NLM/ PMC3277797
  •  go-up   go-down


18. Yokoyama O, Yusup A, Oyama N, Aoki Y, Tanase K, Matsuta Y, Miwa Y, Akino H: Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn; 2006;25(5):461-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats.
  • METHODS: To induce desensitization of C-fiber bladder afferents, we injected resiniferatoxin (0.3 mg/kg, RTX) sub-cutaneously to female Sprague-Dawley rats 2 days prior to left middle cerebral artery occlusion (MCAO) (RTX-CI rats).
  • As controls we used rats without RTX treatment (CI rats).
  • MCAO and insertion of a polyethylene catheter through the bladder dome were performed under halothane anesthesia.
  • RESULTS: Bladder capacity (BC) was markedly reduced after MCAO in both RTX-CI and CI rats. I.v. administration of naftopidil significantly increased BC in CI rats without an increase in residual volume, but it had no effects on BC in RTX-CI rats. I.t. administration of naftopidil significantly increased BC in CI but not in RTX-CI rats.
  • [MeSH-major] Adrenergic alpha-Antagonists / pharmacology. Muscle Hypertonia / drug therapy. Naphthalenes / pharmacology. Nerve Fibers, Unmyelinated / drug effects. Piperazines / pharmacology. Urinary Bladder / drug effects
  • [MeSH-minor] Adrenergic alpha-1 Receptor Antagonists. Animals. Diterpenes / pharmacology. Dose-Response Relationship, Drug. Female. Injections, Intravenous. Injections, Intraventricular. Injections, Spinal. Neurons, Afferent / drug effects. Neurons, Afferent / physiology. Neurotoxins / pharmacology. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673377.001).
  • [ISSN] 0733-2467
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Diterpenes; 0 / Naphthalenes; 0 / Neurotoxins; 0 / Piperazines; A5O6P1UL4I / resiniferatoxin; R9PHW59SFN / naftopidil
  •  go-up   go-down


19. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H: Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol; 2005 Nov;174(5):2032-6
Hazardous Substances Data Bank. PHENYLPROPANOLAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats.
  • PURPOSE: We determined whether the effects of antimuscarinics depend on the suppression of C-fiber bladder afferent nerves.
  • MATERIALS AND METHODS: To induce C-fiber bladder afferent nerve desensitization resiniferatoxin (RTX) (0.3 mg/kg) was injected subcutaneously in female Sprague-Dawley rats 2 days prior to left middle cerebral artery occlusion (MCAO).
  • Insertion of a polyethylene catheter through the bladder dome and MCAO were performed using halothane anesthesia.
  • RESULTS: Bladder capacity (BC) was markedly decreased after MCAO in RTX treated (RTX-CI) and VEH treated (VEH-CI) rats.
  • At the highest dose (2,000 nM/kg) the drug significantly decreased bladder contraction pressure and increased residual volume in RTX-CI and VEH-CI rats.
  • CONCLUSIONS: These results suggest that at low doses tolterodine exerts an inhibitory effect on C-fiber bladder afferent nerves, thereby, improving BC during the storage phase.
  • [MeSH-major] Benzhydryl Compounds / pharmacology. Cresols / pharmacology. Muscarinic Antagonists / pharmacology. Nerve Fibers, Unmyelinated / drug effects. Phenylpropanolamine / pharmacology. Urinary Bladder / innervation. Urinary Incontinence / drug therapy
  • [MeSH-minor] Administration, Intravesical. Afferent Pathways / drug effects. Analysis of Variance. Animals. Disease Models, Animal. Female. Infusions, Intravenous. Probability. Rats. Rats, Sprague-Dawley. Reference Values. Statistics, Nonparametric. Tolterodine Tartrate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217388.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Cresols; 0 / Muscarinic Antagonists; 33RU150WUN / Phenylpropanolamine; 5T619TQR3R / Tolterodine Tartrate
  •  go-up   go-down


20. Gu B, Thor KB, Reiter JP, Dolber PC: Effect of 5-hydroxytryptamine1 serotonin receptor agonists on noxiously stimulated micturition in cats with chronic spinal cord injury. J Urol; 2007 Jun;177(6):2381-5
Hazardous Substances Data Bank. ACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The serotonin 5-hydroxytryptamine(1A/7) receptor agonist (R)-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Sigma) and the 5-hydroxytryptamine(1A/1B/1D) agonist GR-46611 (3-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-(4-methoxybenzyl)acrylamide) (Tocris Cookson, Ellisville, Missouri) inhibit bladder activity during saline infusion into the bladder of cats with chronic spinal cord injury (saline infused, spinal cord injured cats), suggesting an effect on mechanosensitive bladder afferent C fibers or their targets.
  • We investigated the effects of (R)-8-OH-DPAT and GR-46611 on bladder activity in chronic spinal cord injured cats during infusion of dilute acetic acid into the bladder to stimulate chemosensitive bladder afferent C fibers (acid infused, spinal cord injured cats).
  • MATERIALS AND METHODS: Chloralose anesthetized, spinal cord injured cats were catheterized through the bladder dome for filling cystometry during 0.5% acetic acid infusion.
  • Threshold volume, bladder capacity, residual volume, micturition volume and arterial pressure were measured and external urethral sphincter electromyogram was recorded.
  • CONCLUSIONS: Based on differences in the response to GR-46611 in saline vs acid infused, spinal cord injured animals it is tempting to speculate that 2 distinct populations of bladder afferent C fibers (1 chemosensitive and 1 mechanosensitive) can initiate spinal bladder reflexes.
  • Because 5-hydroxytryptamine(1A) receptor agonists increased bladder capacity under saline or acid infused conditions, they are promising candidates for decreasing bladder hyperactivity and increasing bladder capacity in patients with chronic spinal cord injury.
  • [MeSH-major] 8-Hydroxy-2-(di-n-propylamino)tetralin / therapeutic use. Acrylamides / therapeutic use. Indoles / therapeutic use. Serotonin Receptor Agonists / therapeutic use. Spinal Cord Injuries / complications. Urinary Bladder, Neurogenic / drug therapy

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509363.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / GR 46611; 0 / Indoles; 0 / Serotonin Receptor Agonists; 78950-78-4 / 8-Hydroxy-2-(di-n-propylamino)tetralin; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


21. Mohile SG, Schleicher L, Petrylak DP: Treatment of metastatic urachal carcinoma in an elderly woman. Nat Clin Pract Oncol; 2008 Jan;5(1):55-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic urachal carcinoma in an elderly woman.
  • Imaging revealed a large pelvic mass situated on the dome of the bladder, extending from the urachus, without evidence of other sites of metastases.
  • No adjuvant therapy was administered.
  • INVESTIGATIONS: Physical examination, pelvic and complete lymph-node examination, laboratory tests, urine analysis, CT scan of the abdomen and pelvis, chest X-ray, bone scan, cystoscopy, histologic examination of tumor morphology, and MRI of the abdomen and pelvis.
  • DIAGNOSIS: Metastatic urachal adenocarcinoma.
  • MANAGEMENT: Surgical excision combined with cystectomy and pelvic lympadenectomy, chemotherapy with 5-fluorouracil, leucovorin, and irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / secondary. Cystectomy. Lymph Node Excision. Pelvic Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097457.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


22. Murakami S, Chapple CR, Akino H, Sellers DJ, Chess-Williams R: The role of the urothelium in mediating bladder responses to isoprenaline. BJU Int; 2007 Mar;99(3):669-73
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the urothelium in mediating bladder responses to isoprenaline.
  • OBJECTIVES: To investigate whether the responses of the pig bladder to isoprenaline (a nonselective beta-adrenoceptor agonist) are influenced by the presence of an intact urothelium and whether any influence might be attributed to the release of nitric oxide (NO), since stimulation of beta-adrenoceptors induces a direct relaxation of detrusor smooth muscle and beta-adrenoceptors are also present on the urothelium.
  • MATERIAL AND METHODS: Paired (in the presence or absence of urothelium) longitudinal strips of pig bladder dome were set up in tissue baths and the developed tension recorded.
  • In relaxation experiments, isoprenaline relaxed carbachol pre-contracted tissues by approximately 75%, and the potency and maximum relaxation were similar in the absence and presence of the urothelium.
  • In the presence of the urothelium there was a greater shift with 0.1 microm isoprenaline than in denuded tissues.
  • Incubation with L-NNA did not affect the influence of the urothelium on responses to isoprenaline in any experimental group.
  • CONCLUSIONS: The relaxation responses of the bladder to isoprenaline do not appear to involve the urothelium or NO release in vitro.
  • [MeSH-major] Adrenergic beta-Agonists / pharmacology. Isoproterenol / pharmacology. Muscle Contraction / drug effects. Nitric Oxide / metabolism. Urinary Bladder / drug effects. Urothelium / drug effects
  • [MeSH-minor] Animals. Muscle, Smooth / drug effects. Muscle, Smooth / physiology. Swine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17407521.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 31C4KY9ESH / Nitric Oxide; L628TT009W / Isoproterenol
  •  go-up   go-down


23. Levin RM, Juan YS, Whitback C, Perez-Martinez FC, Lin WY: The effect of darifenacin on overactive bladders in female and male rabbits. Int Urol Nephrol; 2008;40(2):303-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our current study utilized a model of bladder instability to compare the effectiveness of darifenacin, a selective m3 muscarinic antagonist, at inhibiting overactive bladder (OAB) dysfunction in both male and female rabbits.
  • The bladder dome was catheterized for monitoring bladder pressure and for cystometry.
  • A ligature was placed around the urethra just distal to the bladder to induce OAB.
  • After OAB developed, the response to four IV doses of darifenacin (0.003; 0.01; 0.03; 0.09 mg/kg) evaluated for their effects. Darifenacin:.
  • These studies provide support for the use of darifenacin in the treatment of OAB.
  • [MeSH-major] Benzofurans / therapeutic use. Muscarinic Antagonists / therapeutic use. Pyrrolidines / therapeutic use. Urinary Bladder, Overactive / drug therapy
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Female. Male. Muscle Contraction / drug effects. Rabbits. Sex Factors

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2005 Jul;48(1):102-9 [15936869.001]
  • [Cites] Life Sci. 1999;64(6-7):395-401 [10069502.001]
  • [Cites] BJU Int. 2003 Dec;92(9):969-71 [14632857.001]
  • [Cites] Drugs Today (Barc). 2005 Jul;41(7):441-52 [16193097.001]
  • [Cites] Br J Pharmacol. 2005 Apr;144(8):1089-99 [15723094.001]
  • [Cites] Neurourol Urodyn. 2002;21(2):167-78 [11857671.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2001;12(1):58-68 [11294534.001]
  • [Cites] Eur Urol. 2003 Jan;43(1):1-5 [12507537.001]
  • [Cites] Urology. 1981 May;17(5):449-53 [7233658.001]
  • [Cites] Acta Physiol Scand. 1989 Sep;137(1):135-41 [2801153.001]
  • [Cites] J Urol. 1998 Nov;160(5):1863-6 [9783975.001]
  • [Cites] Urology. 2004 Dec;64(6 Suppl 1):7-11 [15621221.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):958-62 [14713861.001]
  • [Cites] Eur J Pharmacol. 2004 May 25;492(2-3):243-50 [15178371.001]
  • [Cites] J Urol. 1986 May;135(5):1084-7 [3959235.001]
  • [Cites] Urol Res. 1994;22(4):235-8 [7871636.001]
  • [Cites] BJU Int. 2005 Nov;96(7):1055-62 [16225528.001]
  • [Cites] J Pharmacol Exp Ther. 1980 Dec;215(3):614-8 [7441520.001]
  • [Cites] Life Sci. 1999;65(15):1569-77 [10574223.001]
  • [Cites] Eur J Pharmacol. 2000 Jul 21;400(2-3):287-95 [10988346.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2002;(210):65-71 [12475020.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2002;(210):72-81 [12475021.001]
  • (PMID = 17680338.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R0-1-DK067114
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzofurans; 0 / Muscarinic Antagonists; 0 / Pyrrolidines; APG9819VLM / darifenacin
  •  go-up   go-down


24. Wibberley A, McCafferty GP, Evans C, Edwards RM, Hieble JP: Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat. Br J Pharmacol; 2006 May;148(2):154-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat.
  • Non-selective cyclooxygenase (COX) inhibitors exert effects on lower urinary tract function in several species.
  • The present studies investigated the effects of non- and selective COX inhibitors on bladder irritation in the cat.Chloralose-anaesthetised female cats were catheterised through the bladder dome for cystometric evaluation of bladder responses to intravesical infusion of saline or acetic acid.
  • Bladder capacity, voiding efficiency, threshold pressure, and reflex-evoked bladder contraction amplitude and duration were measured.
  • Pretreatment with indomethacin or ketoprofen (non-selective COX inhibitors; 0.3 mg kg(-1) i.v.) inhibited acetic acid-evoked irritation (characterised by a decrease in bladder capacity in vehicle pretreated animals).
  • FR-122047 (selective COX-1 inhibitor), NS-398 and nimesulide (selective COX-2 inhibitors; 1 and 3 mg kg(-1) i.v.) had no effects on bladder irritation.
  • The present studies suggest that dual COX inhibition is required to attenuate acetic acid-evoked bladder irritation in the cat.
  • [MeSH-major] Cyclooxygenase 1 / blood. Cyclooxygenase 2 / blood. Cyclooxygenase Inhibitors / pharmacology. Urinary Bladder Diseases / drug therapy
  • [MeSH-minor] Acetic Acid / administration & dosage. Acetic Acid / toxicity. Anesthesia. Animals. Cats. Dose-Response Relationship, Drug. Female. Indomethacin / pharmacology. Ketoprofen / pharmacology. Male. Nitrobenzenes / pharmacology. Piperazines / pharmacology. Reflex, Abnormal / drug effects. Sodium Chloride / administration & dosage. Sodium Chloride / pharmacology. Sulfonamides / pharmacology. Thiazoles / pharmacology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • Hazardous Substances Data Bank. ACETIC ACID .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Aug 25;1440(1):127-37 [10477832.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8 [10377455.001]
  • [Cites] J Vet Pharmacol Ther. 2004 Dec;27(6):479-90 [15601442.001]
  • [Cites] J Vet Pharmacol Ther. 2004 Dec;27(6):491-502 [15601443.001]
  • [Cites] J Urol. 2005 Mar;173(3):1011-5 [15711367.001]
  • [Cites] Eur J Pharmacol. 2000 Mar 10;391(1-2):49-54 [10720634.001]
  • [Cites] Br J Pharmacol. 2000 May;130(2):331-8 [10807670.001]
  • [Cites] Clin Pharmacokinet. 2000 May;38(5):377-92 [10843458.001]
  • [Cites] J Pharm Pharmacol. 2000 May;52(5):467-86 [10864134.001]
  • [Cites] Eur J Pharmacol. 2001 Apr 13;417(3):239-48 [11334856.001]
  • [Cites] J Vet Pharmacol Ther. 2001 Feb;24(1):35-42 [11348485.001]
  • [Cites] Biomaterials. 2001 Jul;22(14):2049-56 [11426885.001]
  • [Cites] Am J Vet Res. 2001 Nov;62(11):1755-60 [11703020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14583-8 [11717412.001]
  • [Cites] Br J Pharmacol. 2002 Feb;135(3):782-8 [11834626.001]
  • [Cites] Brain Res. 2002 Aug 16;946(2):290-7 [12137933.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R574-85 [12388444.001]
  • [Cites] Pharmacol Rev. 2004 Sep;56(3):387-437 [15317910.001]
  • [Cites] J Pharmacol Sci. 2004 Aug;95(4):458-65 [15322343.001]
  • [Cites] Invest Urol. 1979 Nov;17(3):244-7 [500325.001]
  • [Cites] Br J Urol. 1981 Feb;53(1):21-8 [7193499.001]
  • [Cites] Jpn J Pharmacol. 1989 Aug;50(4):369-76 [2779004.001]
  • [Cites] Jpn J Pharmacol. 1990 Apr;52(4):587-95 [1692889.001]
  • [Cites] Pharmacol Res. 1992 Jan;25(1):13-20 [1738753.001]
  • [Cites] Gen Pharmacol. 1993 Jan;24(1):105-10 [8482483.001]
  • [Cites] Drugs. 1993;46 Suppl 1:83-90 [7506199.001]
  • [Cites] Inflamm Res. 1998 Oct;47 Suppl 2:S93-101 [9831330.001]
  • [Cites] Am J Physiol. 1999 Jan;276(1 Pt 2):F129-36 [9887088.001]
  • [Cites] Am J Physiol. 1999 Sep;277(3 Pt 2):R786-94 [10484496.001]
  • (PMID = 16547526.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Nitrobenzenes; 0 / Piperazines; 0 / Sulfonamides; 0 / Thiazoles; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 130717-51-0 / 1-((4,5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl)-4-methylpiperazine; 451W47IQ8X / Sodium Chloride; 90Y4QC304K / Ketoprofen; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; Q40Q9N063P / Acetic Acid; V4TKW1454M / nimesulide; XXE1CET956 / Indomethacin
  • [Other-IDs] NLM/ PMC1617054
  •  go-up   go-down


25. Ito M, Okumura K, Nishio Y: [A case of human chorionic gonadotropin-producing bladder cancer]. Hinyokika Kiyo; 2001 Jan;47(1):47-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of human chorionic gonadotropin-producing bladder cancer].
  • Cystoscopy revealed a nodular broad-based cancer at the dome of the bladder.
  • The patient was initially treated by transurethral resection of bladder tumor.
  • Since histological examination showed grade 3 transitional cell carcinoma containing giant cells that were positive for beta-human chorionic gonadotropin (beta-HCG), we made a diagnosis of beta-HCG-producing bladder cancer.
  • Because of his advanced age and poor general condition, the patient underwent partial cystectomy alone without adjuvant chemotherapy.
  • One month later, a chest X-ray film revealed multiple lung metastases, and he developed paraplegia of the lower extremities suggesting spinal metastases.
  • This is, to our best knowledge, the 22nd case report of beta-HCG-producing bladder cancer in Japan.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Chorionic Gonadotropin, beta Subunit, Human / biosynthesis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Cystectomy. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11235222.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


26. Rajasekaran M, Wilkes N, Kuntz S, E Albo M: Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats. Neurourol Urodyn; 2005;24(3):295-300
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats.
  • AIMS: Spontaneously hypertensive rats (SHR) exhibit overactive bladder (OAB) symptoms and have an up-regulated calcium sensitizing RhoA/Rho-kinase pathway in their vascular smooth muscle tissues.
  • This study examined the role of RhoA/Rho-kinase pathway in bladder hyperactivity by evaluating the effect of a specific Rho-kinase inhibitor (Y-27632) on SHR bladder function.
  • A catheter was fixed into the bladder dome and connected to a pressure transducer and an infusion pump.
  • After equilibration, systemic and bladder pressure were recorded.
  • Continuous filling cystometrograms (CMGs) were performed and threshold pressure (TP), peak pressure (PP), and number of voids and non-voiding contractions (NVCs) per unit time recorded.
  • Bladder tissues were evaluated immunohistochemically (IHC) for RhoA protein expression.
  • IHC showed significantly higher RhoA protein expression in SHR bladder tissues.
  • Inhibition of Rho-kinase activity with Y-27632 produced a significant suppression of bladder overactivity.
  • Identification of Rho-kinase isoforms that are bladder-tissue specific and their selective inhibitors may help to disassociate the unwanted hypotensive effects of this approach.
  • [MeSH-major] Amides / pharmacology. Enzyme Inhibitors / pharmacology. Hypertension / complications. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Pyridines / pharmacology. Urinary Incontinence / drug therapy
  • [MeSH-minor] Animals. Blood Pressure. Intracellular Signaling Peptides and Proteins. Male. Muscle Contraction / drug effects. Rats. Rats, Inbred SHR. Rats, Inbred WKY. Urinary Bladder / drug effects. Urinary Bladder / enzymology. Urodynamics / drug effects. rho-Associated Kinases. rhoA GTP-Binding Protein / antagonists & inhibitors. rhoA GTP-Binding Protein / metabolism

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791631.001).
  • [ISSN] 0733-2467
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / Enzyme Inhibitors; 0 / Intracellular Signaling Peptides and Proteins; 0 / Pyridines; 138381-45-0 / Y 27632; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / rho-Associated Kinases; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


27. Levin RM, Whitbeck C, Borow A, Burden O, Leggett RE: Effectiveness of vaginally administered oxybutynin on rabbit bladder function. Urology; 2003 Jun;61(6):1273-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of vaginally administered oxybutynin on rabbit bladder function.
  • OBJECTIVES: To demonstrate the effectiveness of vaginally delivered oxybutynin on bladder function.
  • Oxybutynin has been used for treatment of urge urinary incontinence for more than 20 years.
  • The bladder dome was catheterized for both monitoring of bladder pressure and cystometry.
  • After initial cystometry, acetylcholine (ACh) was injected into the vesical artery at 15-minute intervals for 4 hours.
  • CONCLUSIONS: Vaginally delivered oxybutynin was effective in decreasing bladder compliance and inhibiting intra-arterial ACh-stimulated bladder contractions with little or no effect on the vascular effect of ACh.
  • [MeSH-major] Mandelic Acids / administration & dosage. Mandelic Acids / therapeutic use. Urinary Bladder / drug effects. Urinary Bladder / physiology
  • [MeSH-minor] Acetylcholine / antagonists & inhibitors. Acetylcholine / pharmacology. Administration, Intravaginal. Administration, Oral. Animals. Blood Pressure / drug effects. Female. Muscle Contraction / drug effects. Muscle Contraction / physiology. Muscle, Smooth / drug effects. Muscle, Smooth / physiology. Rabbits. Urinary Incontinence / drug therapy. Urinary Incontinence / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYBUTYNIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12809928.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mandelic Acids; K9P6MC7092 / oxybutynin; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


28. Tazi E, Lalya I, Tazi MF, Ahallal Y, M'rabti H, Errihani H: Treatment of metastatic urachal adenocarcinoma in a young woman: a case report. Cases J; 2009;2:9145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic urachal adenocarcinoma in a young woman: a case report.
  • Imaging revealed a large pelvic mass located on the dome of the bladder, extending from the urachus, with pulmonary metastases.
  • The patient received six cycles of palliative chemotherapy combination 5 fluorouracil and irinotecan with complete response on the pelvic mass and partial response estimated to more than 80% on pulmonary metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1985 Sep;26(3):252-5 [3929441.001]
  • [Cites] Br J Urol. 1987 Oct;60(4):372 [3690215.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2194-204 [8229134.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] Int Urol Nephrol. 1998;30(5):569-73 [9934799.001]
  • [Cites] Urology. 2001 Sep;58(3):462 [11549502.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4319-28 [15514373.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1773-81 [15550582.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3502-8 [15908660.001]
  • [Cites] J Urol. 2006 Jun;175(6):2042-7; discussion 2047 [16697798.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Dec;6(12):1715-21 [17181485.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • (PMID = 20062662.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803942
  •  go-up   go-down


29. Jutley RS, Mason RG: Lessons to be learned: a case study approach. 'Spontaneous' intraperitoneal bladder rupture in a psychiatric patient--with diagnostic difficulties. J R Soc Promot Health; 2001 Jun;121(2):125-7
Hazardous Substances Data Bank. PROCYCLIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons to be learned: a case study approach. 'Spontaneous' intraperitoneal bladder rupture in a psychiatric patient--with diagnostic difficulties.
  • The case described here is that of a 34-year-old woman with a psychiatric disorder who was referred to the local surgical receiving unit with abdominal pain and vomiting.
  • At that time the tests showed a picture of acute renal failure.
  • With the development of increasing abdominal tenderness and pyrexia she was persuaded to have a laparotomy which demonstrated a small tear at the dome of the bladder.
  • The important points demonstrated in this case study are the special clinical difficulties encountered in psychiatric patients, which may consequently lead to delay in diagnosis.
  • The case also highlights the use of procyclidine, commonly used in patients with psychiatric disorders; urinary retention is a recognised side effect of this drug--and it is possible that such retention together with a minor and hence easily overlooked episode of trauma, may have contributed to the patient's condition.
  • [MeSH-major] Rupture, Spontaneous / diagnosis. Urinary Bladder / pathology
  • [MeSH-minor] Adult. Antiparkinson Agents / adverse effects. Antiparkinson Agents / therapeutic use. Comorbidity. Female. Humans. Mental Disorders / drug therapy. Procyclidine / adverse effects. Procyclidine / therapeutic use. Scotland. State Medicine. Treatment Outcome. Urinary Retention / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11467205.001).
  • [ISSN] 1466-4240
  • [Journal-full-title] The journal of the Royal Society for the Promotion of Health
  • [ISO-abbreviation] J R Soc Promot Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiparkinson Agents; C6QE1Q1TKR / Procyclidine
  •  go-up   go-down


30. Leach TD, Sadek SA, Mason JC: An unusual abdominal mass in a renal transplant recipient. Transpl Infect Dis; 2002 Dec;4(4):218-22
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a 72-year-old-man with recurrent bladder carcinoma, abdominal aortic aneurysm repair, and end-stage renal failure due to renovascular disease.
  • He received a cadaveric renal allograft into his left iliac fossa, was given cyclosporin A, azathioprine, and prednisolone triple therapy immunosuppression, and had no rejection episodes.
  • Previous episodes had been investigated with no firm diagnosis made.
  • This time he had right iliac fossa pain of three weeks' duration.
  • Ultrasonography and computed tomography detailed an infiltrating mass associated with the sigmoid colon, which colonoscopy failed to visualise.
  • At laparotomy a 6-cm tumor was removed, with adherent sigmoid colon and bladder dome.
  • [MeSH-major] Abdomen / microbiology. Actinomycosis / diagnosis. Kidney Transplantation / adverse effects
  • [MeSH-minor] Abdominal Abscess. Actinomyces / growth & development. Aged. Antifungal Agents / therapeutic use. Cefaclor / pharmacology. Cefaclor / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male. Opportunistic Infections / diagnosis. Opportunistic Infections / drug therapy. Opportunistic Infections / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12535266.001).
  • [ISSN] 1398-2273
  • [Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society
  • [ISO-abbreviation] Transpl Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Immunosuppressive Agents; 69K7K19H4L / Cefaclor
  •  go-up   go-down






Advertisement